#clinical trials vn

[satasfries]

Lee pov </3 i just wanted a silly doodle of them

Additional Angel pov and alt ver

[bitronic]

[shamistate]

Shamis Tate on the Role of Neurologists in Treating Epilepsy

Epilepsy is a neurological condition that affects millions of people worldwide. It causes recurring seizures due to abnormal brain activity. Managing epilepsy requires specialized care, and neurologists play a vital role in diagnosing, treating, and improving the quality of life for patients. Shamis Tate, a distinguished neurologist specializing in neuropathy and nerve damage, sheds light on how neurologists help individuals living with epilepsy.

Understanding the Role of Neurologists in Epilepsy Treatment

Neurologists are medical doctors who specialize in disorders of the nervous system, including the brain, spinal cord, and nerves. Since epilepsy is a brain-related condition, neurologists are essential in diagnosing and managing it effectively. Their expertise helps patients control seizures and lead healthier lives.

1. Accurate Diagnosis of Epilepsy

One of the first and most crucial steps in treating epilepsy is an accurate diagnosis. Neurologists like Shamis Tate use various diagnostic tools to confirm epilepsy and determine its type. These tools include:

Electroencephalogram (EEG): A test that records brain activity to detect abnormal patterns linked to seizures.

MRI and CT Scans: Imaging tests that help identify structural brain abnormalities or tumors that may cause seizures.

Blood Tests: Used to check for underlying conditions, infections, or genetic factors contributing to epilepsy.

Patient History and Observation: A detailed account of the seizures, triggers, and family history helps neurologists tailor treatment.

2. Developing a Personalized Treatment Plan

Once a diagnosis is confirmed, neurologists create a personalized treatment plan based on the patient’s needs. This may include:

Medications: Anti-seizure drugs are the most common treatment. Neurologists monitor their effectiveness and adjust doses as needed.

Lifestyle Modifications: Patients are advised on sleep, diet, and stress management to reduce seizure risks.

Surgical Options: In cases where medication is ineffective, surgery may be considered to remove the affected brain area causing seizures.

Neuromodulation Therapy: Devices such as vagus nerve stimulators (VNS) help control seizures when medications don’t work.

3. Managing and Monitoring Treatment Progress

Epilepsy treatment is an ongoing process. Neurologists continuously monitor patients to ensure they respond well to treatment. Shamis Tate emphasizes the importance of regular follow-ups, where neurologists:

Assess seizure frequency and severity.

Adjust medications or treatment plans as needed.

Provide guidance on managing side effects of medications.

Educate patients and families about recognizing warning signs and emergency protocols.

4. Addressing Mental and Emotional Well-being

Living with epilepsy can be challenging both physically and emotionally. Neurologists understand the psychological impact of the condition and offer support by:

Referring patients to counselors or support groups.

Addressing anxiety and depression linked to epilepsy.

Educating family members on how to assist during seizures.

5. Advancing Research and New Treatments

Neurologists like Shamis Tate also contribute to epilepsy research, developing new treatments and improving existing ones. Clinical trials and advanced therapies, such as gene therapy and targeted medications, are continuously evolving to provide better outcomes for patients.

Conclusion

Neurologists play a critical role in the diagnosis, treatment, and ongoing management of epilepsy. With their expertise, patients can achieve better seizure control and an improved quality of life. Shamis Tate dedication to neuropathy and nerve damage treatment highlights the importance of specialized neurological care in managing epilepsy effectively. If you or a loved one is experiencing seizures, seeking guidance from a neurologist is the best step toward effective treatment and a healthier future.

[credenceresearchdotblog]

The global Vagus Nerve Stimulator Market is projected to grow from USD 510.2 million in 2023 to an estimated USD 1,201.43 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 11.3% from 2024 to 2032. The vagus nerve stimulator (VNS) market has been gaining significant traction over the past few years, driven by advancements in medical technology, increasing awareness of neurological disorders, and the growing prevalence of treatment-resistant diseases. This article delves into the current market landscape, its key drivers, challenges, and future opportunities.

Browse the full report https://www.credenceresearch.com/report/vagus-nerve-stimulator-market

Understanding Vagus Nerve Stimulation

The vagus nerve, one of the longest cranial nerves in the human body, plays a crucial role in regulating involuntary body functions such as heart rate, digestion, and mood. Vagus nerve stimulation involves the use of electrical impulses to modulate its activity, providing therapeutic benefits for various conditions. VNS devices are either implantable or non-invasive, offering tailored solutions for medical practitioners and patients alike.

Market Drivers

1. Rising Prevalence of Neurological and Psychiatric Disorders Neurological conditions such as epilepsy, depression, and anxiety disorders have been on the rise globally. According to the World Health Organization (WHO), approximately 50 million people worldwide suffer from epilepsy, many of whom are resistant to conventional treatments. VNS has proven to be a viable alternative for such cases, propelling its market demand.

2. Expanding Applications in Chronic Diseases Beyond epilepsy and depression, VNS is being explored for other conditions, including migraines, Alzheimer's disease, and inflammatory disorders. This broadening application base is a significant factor driving market growth.

3. Technological Advancements The development of non-invasive VNS devices has transformed the landscape, providing patients with safer, more accessible options. Innovations such as wireless and wearable devices have further enhanced convenience and compliance.

4. Growing Awareness and Investment Increased awareness of the benefits of VNS among healthcare providers and patients, coupled with investments from governments and private organizations, has spurred market expansion. Clinical trials and research funding have also played a pivotal role in uncovering new applications for VNS technology.

Market Challenges

1. High Costs and Limited Reimbursement Policies The cost of VNS devices and implantation procedures can be prohibitive, especially in developing economies. Additionally, inadequate reimbursement frameworks hinder accessibility, limiting market penetration.

2. Risk of Side Effects While VNS is generally considered safe, potential side effects such as hoarseness, throat pain, and breathing difficulties can deter patients from opting for the treatment.

3. Regulatory Hurdles Stringent regulatory requirements for medical device approval can delay the launch of innovative products, impacting market growth.

Future Outlook

The vagus nerve stimulator market is poised for sustained growth, driven by ongoing research and development, technological innovations, and expanding therapeutic applications. Strategic collaborations between key players, healthcare providers, and research institutions are expected to unlock new opportunities.

Key players

Soterix Medical Inc.

MicroTransponder Inc.

Beijing PINS Medical Co., Ltd.

SetPoint Medical Corporation

Parasym Ltd

tVNS Health GmbH

Neuropix Company Ltd.

electroCore, Inc.

LivaNova PLC

Segments

Based on Product

Implantable VNS devices

External VNS devices

Based on Application

Epilepsy

Depression

Others

Based on End User

Hospitals

Neurology clinics

Others

Based on Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/vagus-nerve-stimulator-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tritonmarketresearchamey]

Epilepsy Devices Market: Tech Trends 2022-2028

According to the WHO, epilepsy is a chronic brain disorder that affects 50 million individuals, making it one of the most prevalent neurological conditions worldwide. It is estimated that with access to early detection and appropriate care, 70% of the population diagnosed with epilepsy may live seizure-free. According to our estimates, the global epilepsy devices market was valued at $669.73 million in 2021 and is expected to reach $1157.58 million by 2028, growing at a CAGR of 8.16% during the forecast period 2022-2028.

Government institutions worldwide are focused on starting initiatives to create innovative epilepsy devices with AI and machine learning integration. Additionally, organizations that support research need to encourage high-quality comparative efficacy trials and sufficient data to guide therapeutic practice in epilepsy. As a result of these technologically advanced equipment and increasing drug trials, the market for epilepsy devices is anticipated to grow throughout the forecast period.

Epilepsy Devices - Key Detection Methodologies

Currently, several wearable technologies can detect seizures, collect data, and alert caregivers. Although with technological advancements, the ability to detect seizure-related alterations increases. Top trends backing this tech boom include:

Wearable devices are estimated to be the fastest-growing device type during the forecast period. Monitoring epileptic patients is crucial, as 20% of epileptics only have seizures while asleep, 40% only have seizures while awake, and 35% have seizures both when they are awake and asleep. With technologically advanced non-invasive wearable sensors, measuring accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the conventional clinical environment have become effective.

Vagus Nerve Stimulation (VNS) has emerged as the fastest-growing application category. VNS Therapy has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for age 4 years and above to treat drug-resistant epilepsy or refractory epilepsy. VNS has been reportedly beneficial in many patients, including the ones with posttraumatic epilepsy (PTE). PTE is a common consequence of traumatic brain injury and accounts for about 20% of symptomatic epilepsy cases.

As per estimates, Electroencephalography lead the detection and prediction devices type segment in 2021 and is expected to maintain its stronghold during the forecast period. There is growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring in an easy‐to‐use format. Despite the availability of these new EEG solutions, their adoption is still limited in clinical practice, mainly because of the unfamiliarity of healthcare and biomedical research sectors with the technology and its application.

Strategic Initiatives and Government Approvals

Different end-users, such as homecare settings, hospitals, and clinics, are utilizing epilepsy devices. The manufacturers of epilepsy monitoring devices are likely to gain prominent business opportunities from the hospital & clinics segment owing to the rise in the use of EEG monitoring and emergency medical services.

The government authorities of several developing nations, including India and China, are focusing on developing sturdy healthcare infrastructure. As a result, operating players are expected to gain sizable growth prospects in the region during the forecast period. Owing to this, the Asia Pacific epilepsy devices market is anticipated to witness the fastest growth with a CAGR of 8.38% throughout the forecast period.

In addition, companies are also focusing on launching novel devices for children. Moreover, companies are also using organic and inorganic strategies, including mergers and acquisitions, to stay ahead of the competition. Some of these include:

In September 2022, Boston Scientific Corporation’s current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling. The company also received FDA 510(k) clearance for the EMBOLD Fibered Detachable Coil, which reduces the blood flow rate in the peripheral vasculature.

In July 2022, Medtronic PLC received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform to leverage machine learning.

In November 2021, NeuroPace, Inc. received an Investigational Device Exemption (IDE) from the FDA to study the company’s RNS System to treat primary generalized epilepsy in patients aged 12 and above.

Way Forward

With technological advancements, epilepsy detection devices with exceptionally low false alarm rates have recently been developed. They are based on computationally intensive algorithms and employed in implanted systems for pre-surgical monitoring. Recent research has produced encouraging findings for probabilistic seizure risk projections using long-term wearable technology and electronic seizure diaries. The symptoms, mood, and cognitive function of an individual may also have predictive significance. Therefore, technological advances in non-invasive wearable sensors are anticipated to create growth opportunities for the epilepsy devices market.

 

FAQ:

Q1) What are the key end-users of the epilepsy devices market?

The key end-users in the epilepsy devices market include hospitals & clinics, neurology centers, homecare settings, and other end-users.

Q2) Which region leads the global epilepsy devices market?

North America leads the global epilepsy devices market.

[bestneurologistinmumbai]

When it comes to managing and treating seizures, finding a skilled and experienced specialist is crucial. In Mumbai, Dr. Kharkar stands out as a leading name in the field of neurology, particularly for patients seeking advanced seizure treatment. With a comprehensive approach to diagnosis, treatment, and patient care, Dr. Kharkar has established a reputation for excellence.

Expertise and Qualifications

Dr. Kharkar is a board-certified neurologist with specialized training in epileptology, the branch of medicine that deals with the study and treatment of epilepsy and seizure disorders. His extensive education and training, including a residency in neurology and a fellowship in epilepsy, equip him with the knowledge and skills to handle even the most complex seizure cases.

Comprehensive Diagnostic Approach

Dr. Kharkar utilizes state-of-the-art diagnostic tools to accurately diagnose the type and cause of seizures. His diagnostic process includes:

Detailed Patient History: Understanding the patient's medical history, seizure characteristics, and triggers.

Advanced Imaging: MRI and CT scans to identify structural abnormalities in the brain.

Electroencephalogram (EEG): Monitoring electrical activity in the brain to detect abnormal patterns.

Blood Tests: Identifying potential underlying conditions that may contribute to seizures.

Personalized Treatment Plans

Recognizing that every patient is unique, Dr. Kharkar develops personalized treatment plans tailored to individual needs. These plans may include:

Medication Management: Prescribing anti-seizure medications tailored to the specific type of seizure and patient response.

Surgical Options: For patients who do not respond to medication, Dr. Kharkar offers advanced surgical interventions, such as resective surgery or vagus nerve stimulation (VNS).

Lifestyle Modifications: Advising on dietary changes, sleep hygiene, and stress management techniques that can help reduce seizure frequency.

Continuous Monitoring: Using devices like ambulatory EEG to monitor seizures over an extended period and adjust treatment as necessary.

Compassionate Patient Care

Beyond his clinical expertise, Dr. Kharkar is known for his compassionate approach to patient care. He takes the time to listen to his patients, addressing their concerns and providing education about their condition and treatment options. His goal is to empower patients and their families with the knowledge and support they need to manage seizures effectively.

Cutting-Edge Research and Innovation

Dr. Kharkar stays at the forefront of medical research, continually updating his practice with the latest advancements in seizure treatment. His involvement in clinical trials and research ensures that his patients have access to the most innovative therapies available.

Conveniently Located

Dr. Kharkar's clinic is conveniently located in Mumbai, making it accessible for patients from all parts of the city and beyond. His clinic is equipped with modern facilities, ensuring a comfortable and efficient experience for all patients.

For anyone seeking expert care for seizure disorders in Mumbai, Dr. Kharkar offers a combination of advanced medical expertise, personalized treatment plans, and compassionate care, making him the ideal choice for managing and treating seizures effectively.

[healthcaremarketfmi]

Muscle Stimulation Devices Market Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2028

In 2022, sales of muscle stimulation devices are expected to reach US$ 694.7 Mn. The performance of the global muscle stimulation devices market is expected to witness immensely impactful developments, with potential improvements in the recovery of stroke through nerve stimulation. With rising rate of AIS (acute ischemic stroke), the focus has been shifted to improving the associated stages of stroke care, including prevention, intervention, and rehabilitation. The Ohio State University has been conducting a new clinical trial to shorten the motor skills recovery period in stroke patients, via VNS (vagus nerve stimulation).

Download our Sample Report to discover how recent industry developments, like@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1140

The trial involves the use of a device – Vivistim, which has been developed by MicroTransponder, a Dallas-based company. The device functions by coupling VNS with the muscle movement, during rehabilitation. It is supposed to build up the motor function, learning, and memory, drastically improving the post-stroke outcome thereby. This nerve stimulation therapy, if used in tandem with appropriate interventions, can potentially result in excellent rehabilitation, minimizing the impact of complications that may follow the treatment process. If Vivistim delivers positive results and enables stroke patients to regain their motor function early, the market participants may witness multiple doors of opportunities in the rehabilitative treatment area.

Key Companies to Focus on Strong Distribution Channel Development & Suppliers to Strengthen Presence in Emerging Markets

New and innovative product launches such as wireless devices are being considered by manufacturers as the key to achieve enhanced device capabilities, which is presumed to trigger sales in long term. To expand market shares and improve distribution network through the next decade, several players are prioritizing strategic partnerships, i.e. distribution agreements for their product offerings. Enhanced distribution will also help the stakeholders penetrate various untapped regional markets.

Any Questions, Reach Out To Us @ https://www.futuremarketinsights.com/ask-question/rep-gb-1140

Key players in the global muscle stimulation devices market are focusing on development of new pain management methods and techniques. Adoption of innovative marketing strategy by muscle stimulation device manufacturers is attributed to their gradually increasing market value share. Increased focus on strengthening of distribution channel will reportedly be the key for market expansion in emerging economies. On the flipside, suppliers are likely to consider patient needs as a top priority, while ensuring the supply of high-quality products to end users. Stakeholders are strengthening product portfolio by launching new products with improved features, and through strategic mergers and acquisitions. Moreover, a growing number of local players in the muscle stimulation devices market is expected to result in creating a fragmented market, since the market is already led by smaller-sized firms catering to domestic customer demands.

Muscle Stimulation Devices to Face Passive Growth

Despite immense scope for innovation in product development and applications, the global market for muscle stimulation devices is projected to observe sluggish growth over the next decade. As prompted by a recent research study by Future Market Insights, the global muscle stimulation devices market will expand at a CAGR of 3.9% during 2018-2028, attaining a value of over US$ 870 Mn by 2028 end. High price point will remain a longstanding factor limiting widespread adoption of muscle stimulators. Stringent regulatory norms regarding the launch and use of muscle stimulation devices is also anticipated to hinder market growth in upcoming decade.

By value, North America and Western Europe are expected to represent the dominant markets for muscle stimulation devices, whereas developing economies such as APEJ, Latin America, and Eastern Europe will reportedly exhibit relatively promising performance over the projection period.

[mrudula01]

Epilepsy Devices Market: Tech Trends 2022-2028

Lifesciences

09, December 2022

According to the WHO, epilepsy is a chronic brain disorder that affects 50 million individuals, making it one of the most prevalent neurological conditions worldwide. It is estimated that with access to early detection and appropriate care, 70% of the population diagnosed with epilepsy may live seizure-free. According to our estimates, the global epilepsy devices market was valued at $669.73 million in 2021 and is expected to reach $1157.58 million by 2028, growing at a CAGR of 8.16% during the forecast period 2022-2028.

Government institutions worldwide are focused on starting initiatives to create innovative epilepsy devices with AI and machine learning integration. Additionally, organizations that support research need to encourage high-quality comparative efficacy trials and sufficient data to guide therapeutic practice in epilepsy. As a result of these technologically advanced equipment and increasing drug trials, the market for epilepsy devices is anticipated to grow throughout the forecast period.

Epilepsy Devices - Key Detection Methodologies

Currently, several wearable technologies can detect seizures, collect data, and alert caregivers. Although with technological advancements, the ability to detect seizure-related alterations increases. Top trends backing this tech boom include:

Wearable devices are estimated to be the fastest-growing device type during the forecast period. Monitoring epileptic patients is crucial, as 20% of epileptics only have seizures while asleep, 40% only have seizures while awake, and 35% have seizures both when they are awake and asleep. With technologically advanced non-invasive wearable sensors, measuring accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the conventional clinical environment have become effective.

Vagus Nerve Stimulation (VNS) has emerged as the fastest-growing application category. VNS Therapy has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for age 4 years and above to treat drug-resistant epilepsy or refractory epilepsy. VNS has been reportedly beneficial in many patients, including the ones with posttraumatic epilepsy (PTE). PTE is a common consequence of traumatic brain injury and accounts for about 20% of symptomatic epilepsy cases.

As per estimates, Electroencephalography lead the detection and prediction devices type segment in 2021 and is expected to maintain its stronghold during the forecast period. There is growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring in an easy‐to‐use format. Despite the availability of these new EEG solutions, their adoption is still limited in clinical practice, mainly because of the unfamiliarity of healthcare and biomedical research sectors with the technology and its application.

Strategic Initiatives and Government Approvals

Different end-users, such as homecare settings, hospitals, and clinics, are utilizing epilepsy devices. The manufacturers of epilepsy monitoring devices are likely to gain prominent business opportunities from the hospital & clinics segment owing to the rise in the use of EEG monitoring and emergency medical services.

The government authorities of several developing nations, including India and China, are focusing on developing sturdy healthcare infrastructure. As a result, operating players are expected to gain sizable growth prospects in the region during the forecast period. Owing to this, the Asia Pacific epilepsy devices market is anticipated to witness the fastest growth with a CAGR of 8.38% throughout the forecast period.

In addition, companies are also focusing on launching novel devices for children. Moreover, companies are also using organic and inorganic strategies, including mergers and acquisitions, to stay ahead of the competition. Some of these include:

In September 2022, Boston Scientific Corporation’s current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling. The company also received FDA 510(k) clearance for the EMBOLD Fibered Detachable Coil, which reduces the blood flow rate in the peripheral vasculature.

In July 2022, Medtronic PLC received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform to leverage machine learning.

In November 2021, NeuroPace, Inc. received an Investigational Device Exemption (IDE) from the FDA to study the company’s RNS System to treat primary generalized epilepsy in patients aged 12 and above.

Way Forward

With technological advancements, epilepsy detection devices with exceptionally low false alarm rates have recently been developed. They are based on computationally intensive algorithms and employed in implanted systems for pre-surgical monitoring. Recent research has produced encouraging findings for probabilistic seizure risk projections using long-term wearable technology and electronic seizure diaries. The symptoms, mood, and cognitive function of an individual may also have predictive significance. Therefore, technological advances in non-invasive wearable sensors are anticipated to create growth opportunities for the epilepsy devices market.

FAQ:

Q1) What are the key end-users of the epilepsy devices market?

The key end-users in the epilepsy devices market include hospitals & clinics, neurology centers, homecare settings, and other end-users.

Q2) Which region leads the global epilepsy devices market?

North America leads the global epilepsy devices market.

[research--blog]

Neuromodulation Systems Market to be Worth $10.29 Billion by 2030

According to a new market research report titled, ‘Neuromodulation Systems Market by Type (Spinal Cord, Sacral Nerve, Vagus Nerve, Deep Brain Stimulation), Application (Parkinson's Disease, Tremor, Depression, Epilepsy, Gastroparesis, Obesity, Psychiatry, Neurology, Pediatry) - Global Forecast to 2030,’ published by Meticulous Research®, the neuromodulation systems market is projected to reach $10.29 billion by 2030, at a CAGR of 8.2% from 2023 to 2030.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5476

Neuromodulation devices are medical devices that alter the activity of specific nerve fibers by delivering electrical, chemical, or other forms of stimulation to target areas in the body. These devices are used to treat various conditions, such as chronic pain, movement disorders, depression, and others, by changing the activity of nerve cells (neurons) in a specific area.

Neuromodulation devices can be implantable or external and include, for example, spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, sacral nerve stimulators, and transcutaneous electrical nerve stimulators (TENS). Neuromodulation aims to modify neural activity in a controlled and reversible manner to alleviate symptoms or improve function.

The factors driving the growth of this market are the high prevalence of neurological disorders and nerve injuries, advancements in neuromodulation & neurostimulation technologies, and expanding applications of neuromodulator systems due to clinical trials.

Furthermore, emerging economies and the increasing demand for non-invasive devices are expected to offer growth opportunities for market expansion. However, the shortage of skilled healthcare professionals and regulatory barriers and recall of neuromodulator systems pose a major challenge to the growth of the neuromodulation systems market.

Advancements in Neuromodulation Systems to Drive the Growth of the Neuromodulation Systems Market

The advancements in neuromodulation technology have been largely driven by the miniaturization of devices, the increasing complexity of tasks they can perform, and the improved understanding of neural responses to stimulation. As technology in integrated circuits and batteries has improved, the size of neuromodulation devices has decreased; however, the functional requirements for these devices have become more complex.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5476

Key factors driving the development of neuromodulation therapies are the growing need for improved surgical procedures, increased control over programming parameters, and easier patient interactions. However, there is a growing recognition that future advancements must focus on meeting the needs of patients outside of clinical settings while also keeping healthcare providers informed. This has led to a focus on advancements in diagnostics, therapy, and disease management within the field of neuromodulation, which enables the seamless integration of digital technology with these therapies for improved patient care.

The neuromodulation systems market is segmented by Type (Internal Neuromodulation {Spinal Cord Stimulation (SCS) [Failed Back Surgery Syndrome (FBSS), Post-surgical Pain, Arachnoiditis, Other SCS Applications], Deep Brain Stimulation (DBS) [Parkinson's Disease, Essential Tremor, Depression, Other DBS Applications], Sacral Nerve Stimulation (SNS) [Urine incontinence, Fecal incontinence], Vagus Nerve Stimulation (VNS) [Epilepsy, Depression], Gastric Electrical Stimulation [Gastroparesis, Obesity]}, External Neuromodulation {Transcranial Magnetic Stimulation (TMS) [Psychiatry, Neurology, Pediatry, Other TMS Applications], Transcutaneous Electrical Nerve Stimulation [Deperession, Other TENS Applications], Respiratory Electrical Stimulation}) and Geography. The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

Quick Buy – Neuromodulation Systems Market Research Report: https://www.meticulousresearch.com/Checkout/14012265

Based on type, the neuromodulation systems market is segmented into internal neuromodulation and external neuromodulation. In 2023, the internal neuromodulation segment is expected to account for the largest share of this market. The factors contributing to the large market share of this segment are effectiveness, long-term use, durability, increased safety, and improved patient compliance offered by internal neuromodulation systems. Internal neuromodulation systems do not require patients to wear or carry external equipment, making them more convenient and comfortable. The internal neuromodulation segment is further subsegmented into spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, and gastric electrical stimulation. In 2023, the spinal cord segment is expected to account for the largest share of the market. Spinal cord stimulators are used to treat and manage chronic pain, failed back surgery syndrome, arachnoiditis, post-surgical pain, heart pain, injuries to the spinal cord, and other conditions. The increasing prevalence of these target diseases among the aging population contributes to the high demand for spinal cord stimulators.

In 2023, North America is expected to account for the largest share of the neuromodulation systems market due to the well-established healthcare system, significant investments in healthcare, high prevalence of neurological disorders among the geriatric population, and availability of advanced treatment options.

The report also includes an extensive assessment of the key growth strategies adopted by major market players between 2020 and 2023. The neuromodulation systems market has recently witnessed several product launches, collaborations, and acquisitions.

Some of the key players operating in the neuromodulation systems market are LivaNova PLC (U.K.), Nevro Corp. (U.S.), Medtronic plc (Ireland), Abbott Laboratories (U.S.), NeuroSigma, Inc. (U.S.), Neuronetics, Inc. (U.S.), NeuroPace, Inc. (U.S.), Bioventus Inc. (U.S.), MicroTransponder, Inc. (U.S.), Soterix Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), Synapse Biomedical Inc. (U.S.), and Aleva Neurotherapeutics SA (Switzerland).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/neuromodulation-systems-market-5476

Scope of the Report:

Neuromodulation Systems Market, by Type

Internal Neuromodulation

Spinal Cord Stimulation (SCS), by Application

Failed Back Surgery Syndrome

Post-surgical Pain

Arachnoiditis

Other SCS Applications

Deep Brain Stimulation (DBS), by Application

Parkinson's Disease

Essential Tremor

Depression

Other DBS Applications

Sacral Nerve Stimulation, by Application

Urine incontinence

Fecal incontinence

Vagus Nerve Stimulation (VNS), by Application

Epilepsy

Depression

Other VNS Applications

Gastric Electrical Stimulation, by Application

Gastroparesis

Obesity

External Neuromodulation

Transcranial Magnetic Stimulation (TMS), by Application

Psychiatry

Neurology

Pediatry

Other TMS Applications

Transcutaneous Electrical Nerve Stimulation (TENS)

Depression

Other TENS Applications

Respiratory Electrical Stimulation

Note: *Other SCS Applications include heart pain (angina), injuries to the spinal cord, nerve-related pain, peripheral vascular disease, and complex regional pain syndrome.

*Other DBS Applications include Dystonia and obsessive-compulsive disorder (OCD) or Tourette disorder.

*Other VNS Applications include stroke and migraine

*Other TMS Applications include anxiety and generalized anxiety disorder (GAD).

* Other TENS Applications include acute pain and chronic pain.

Neuromodulation Systems Market, by Geography

North America

U.S.

Canada

Europe

Germany

U.K.

France

Italy

Spain

Rest of Europe (RoE)

Asia-Pacific (APAC)

China

Japan

India

Rest of APAC (RoAPAC)

Latin America

Brazil

Mexico

Rest of Latin America (RoLATAM)

Middle East & Africa

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5476

[bolgs]

NIU COLLEGE (Staff and Faculty Part II)

Sandra Pirio

Ms. Pirio has taught CNA classes based on guidelines identified by certification requirements established by the State of California Department of Health Administered tests. She has years of experience working as a Licensed Vocational Nurse and also teaching CAN classes in North Valley Nursing Center, and St. Jude Nursing Center

Wanda Pacis Garcia

Ms. Garcia obtained her degree in Bachelor of Science Health in professional Development and Advanced Patient Care from Grand Canyon University. Her experiences include working as LVN Field Nurse, Clinical Instructor, VN Clinical Instructor, Utilization Review Nurse, Relief Nurse, VN Staff Nurse, and Tele Recruiter for American Red Cross. She has many years of experience teaching at various vocational colleges.

Jonathan Arnold, Esq.

Oxford University - Law,University of Southern California, USC - B.A.,California State University Northridge, CSUN - Certificate, Contract Management,Pepperdine University - Certificate, Mediation

In addition to his research work and being the voice of the Finz Advance Series on California Evidence, Civil Procedure & Discovery (http://finz.pincusproed.com/index.cfm), he is the host of Don’t Sign That, an Entertainment Law Podcast for the Starving, and Not So Starving, Artist! (www.dontsignthatpodcast.com), Mr. Arnold is also the author of one of the most prominent blogs on Art Law (www.theartslaw.blogspot.com) and is a guest columnist on Medieval Law (www.darkag.es/vi5Au0). Other speaking engagements of note include The Art of Entertainment Deal making, MCLE presentations on Proprietary Information Agreements, Indemnity Types & Insurance and Federal Legal Issues in Contractual Risk Management, which he co-chaired with NASA’s former Chief Counsel at the Dryden Flight Research Center, Edwards Air Force Base. He has also had articles published in the Los Angeles Daily Journal, Bar Notes Magazine, and Contract Management Magazine and was a featured, regular columnist for The Patch (http://shermanoaks.patch.com/users/jonathanarnold-esq/blog_posts).

An active member of the California Bar, Mr. Arnold is also admitted to practice before the U.S. District Court, Central District. He is a member of the American Bar Association (ABA), the California Copyright Conference (CCC), the Los Angeles County Bar Association, the San Fernando Valley Bar Association and the past President of the San Fernando Valley Chapter of the National Contract Management Association (NCMA).

Mark Robinson, PHR.

Master of Business Administration - Benedict University -Lisle, IllinoisBachelors of Science in Management - National-Louis University - Wheaton, IllinoisProfessional Human Resource Certification program (PHR) - Human Resource Certification InstituteHuman Resource Management Certification program - University of California - Los AngelesSeveral Leadership & Recruiting Courses - US Army

Mr. Robinson has over 25 years of solid, on-the-job Human Resource experience, proven success in leading Human Resource operations in diverse organizations across multiple states and achieving bottom line results. He is a great Motivational Leader, analytical thinker, productive problem-solver with excellent people skills. Mr. Robinson is a vibrant communicator, delivering engaging recruitment presentations and he holds many professional certifications.

Brandon Klock

Watterson College Sherman Oaks, CA - Paralegal CertificateLos Angeles Pierce College – Psychology

Mr. Klock is an Independent Contractor Paralegal, Litigation Strategy & Transactional Consultant for Small & Boutique Businesses & Civil Litigation Firms. Litigation services include composition of pleading, pretrial motions, motions for summary judgment, oppositions, trial preparation & trial support in real Estate, fraud, breach of contract & other business litigation matters.

Mr. James Liko

Mr. Liko has many years of experience in HVAC/R industry which includes LA City Fire Departmentcertification in the event of an earthquake and other disasters. He has worked in his field as an HVAC/R technician and HVAC instructor for many colleges.

Some of his Experiences include but are not limited to:

Planning and scheduling preventive maintenance projects, preparing material lists, ordering materials, preparing job estimates, supervision, coordination and assignment of work to personnel and inspection of completed projects.

Inspection of HVAC equipment and related controls for needed repairs and maintenance.

Operating computer automation energy management system and maintaining records and writing reports.

Instruction and training of students for the HVAC field.

Instruction include HVAC controls, control system theory, control hardware, simple and complex control systems, supervisory control and the use of computer in control systems.

Laboratory and clinical instruction in accordance with the curriculum.

Hector Manuel Quintanilla

Mr. Hector Quintanilla has over twenty five years of experience and strong knowledge of automotive and heavy-duty equipment and parts; maintenance practices; procedures and requirements for automotive equipment and safe work practices and conditions. His remarkable ability to: maintain, repair, overhaul, adjust, install and check a variety of automotive equipment; reading and understanding electrical schematics, manuals, and other information, makes him a great candidate to teach these subjects.

Mr. Quintanilla has the ability to troubleshoot malfunctions in automotive engine, transmission, break and heavy-duty equipment and determine repair requirements. He understands instructions and communicates and teaches others effectively; fill out forms and keep records; and interact with others in a professional manner.

He has in-depth knowledge and ability to identify tools, shop equipment, and use the tools, excellentknowledge of body and frame construction, sound knowledge of employee policies and procedure, strong ability to read automotive diagrams, schematics, blueprints, and reference manuals, exceptional ability to instruct and supervise the disassembly and assembly of auto engines and parts.

Courtesy : NIU COLLEGE CATALOG (niu-college.com)

Trade School Los Angeles

[tritonmarketresearch]

Epilepsy Devices Market: Tech Trends 2022-2028

According to the WHO, epilepsy is a chronic brain disorder that affects 50 million individuals, making it one of the most prevalent neurological conditions worldwide. It is estimated that with access to early detection and appropriate care, 70% of the population diagnosed with epilepsy may live seizure-free. According to our estimates, the global epilepsy devices market was valued at $669.73 million in 2021 and is expected to reach $1157.58 million by 2028, growing at a CAGR of 8.16% during the forecast period 2022-2028.

Government institutions worldwide are focused on starting initiatives to create innovative epilepsy devices with AI and machine learning integration. Additionally, organizations that support research need to encourage high-quality comparative efficacy trials and sufficient data to guide therapeutic practice in epilepsy. As a result of these technologically advanced equipment and increasing drug trials, the market for epilepsy devices is anticipated to grow throughout the forecast period.

Epilepsy Devices - Key Detection Methodologies

Currently, several wearable technologies can detect seizures, collect data, and alert caregivers. Although with technological advancements, the ability to detect seizure-related alterations increases. Top trends backing this tech boom include:

Wearable devices are estimated to be the fastest-growing device type during the forecast period. Monitoring epileptic patients is crucial, as 20% of epileptics only have seizures while asleep, 40% only have seizures while awake, and 35% have seizures both when they are awake and asleep. With technologically advanced non-invasive wearable sensors, measuring accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the conventional clinical environment have become effective.

Vagus Nerve Stimulation (VNS) has emerged as the fastest-growing application category. VNS Therapy has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for age 4 years and above to treat drug-resistant epilepsy or refractory epilepsy. VNS has been reportedly beneficial in many patients, including the ones with posttraumatic epilepsy (PTE). PTE is a common consequence of traumatic brain injury and accounts for about 20% of symptomatic epilepsy cases.

As per estimates, Electroencephalography lead the detection and prediction devices type segment in 2021 and is expected to maintain its stronghold during the forecast period. There is growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring in an easy‐to‐use format. Despite the availability of these new EEG solutions, their adoption is still limited in clinical practice, mainly because of the unfamiliarity of healthcare and biomedical research sectors with the technology and its application.

Strategic Initiatives and Government Approvals

Different end-users, such as homecare settings, hospitals, and clinics, are utilizing epilepsy devices. The manufacturers of epilepsy monitoring devices are likely to gain prominent business opportunities from the hospital & clinics segment owing to the rise in the use of EEG monitoring and emergency medical services.

The government authorities of several developing nations, including India and China, are focusing on developing sturdy healthcare infrastructure. As a result, operating players are expected to gain sizable growth prospects in the region during the forecast period. Owing to this, the Asia Pacific epilepsy devices market is anticipated to witness the fastest growth with a CAGR of 8.38% throughout the forecast period.

In addition, companies are also focusing on launching novel devices for children. Moreover, companies are also using organic and inorganic strategies, including mergers and acquisitions, to stay ahead of the competition. Some of these include:

In September 2022, Boston Scientific Corporation’s current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling. The company also received FDA 510(k) clearance for the EMBOLD Fibered Detachable Coil, which reduces the blood flow rate in the peripheral vasculature.

In July 2022, Medtronic PLC received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform to leverage machine learning.

In November 2021, NeuroPace, Inc. received an Investigational Device Exemption (IDE) from the FDA to study the company’s RNS System to treat primary generalized epilepsy in patients aged 12 and above.

Way Forward

With technological advancements, epilepsy detection devices with exceptionally low false alarm rates have recently been developed. They are based on computationally intensive algorithms and employed in implanted systems for pre-surgical monitoring. Recent research has produced encouraging findings for probabilistic seizure risk projections using long-term wearable technology and electronic seizure diaries. The symptoms, mood, and cognitive function of an individual may also have predictive significance. Therefore, technological advances in non-invasive wearable sensors are anticipated to create growth opportunities for the epilepsy devices market.

[satasfries]

Sorry i was gone i have decided i wanna revamp my style by relearning some stuff so on blahblah anyway i decided to watch MBH playthru of Clinical Trials and I am sorry but I am whipped for Lee he's mentally ill and whined so I was struck with inspiration

[moremedtech]

Brain Stimulation study shows high electrical frequency stimulation can activate specific nerve fibers in the body

Brain Stimulation study shows high electrical frequency stimulation can activate specific nerve fibers in the body. Feinstein Institutes Bioelectronic Medicine Researchers Target Specific Vagus Nerve Fibers for More Precise, Effective Stimulation. MANHASSET, N.Y, November 04, 2022 - Electrically stimulating the vagus nerve has shown potential to treat inflammatory diseases, including rheumatoid arthritis, lupus and diabetes. Now, a team of bioelectronic medicine scientists at The Feinstein Institutes for Medical Research is one step closer to developing more precise, selective neuromodulation techniques. A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.

Dr. Stavros Zanos recently led the study, which targets specific fibers in the vagus nerve for more precise electrical stimulation. (Credit: Feinstein Institutes) The research study, led by Stavros Zanos, MD, PhD, associate professor at the Feinstein Institutes Institute of Bioelectronic Medicine, measured how vagus nerve stimulation (VNS) using kHz stimulation – an electrical stimulus that is commonly used to block nerve conduction at over 1,000 pulses per second affects the activity of different types of vagal fibers. Previous VNS therapies would stimulate the whole nerve bluntly, without targeting specific fibers, which could cause adverse effects and less effective therapy. For example, in past clinical trials, side effects from the vocal cords and from coughing reflex prevented clinicians from delivering the full dose of VNS, and thus limited the therapeutic effect. “The vagus nerve is one of the most important nerves in our body, which helps us maintain our daily functions like breathing and our heart rate. Being able to target certain nerve fibers is a huge step for precision stimulation,” said Dr. Zanos, senior author of the paper. “This selective stimulation in the vagus nerve has not been achieved until now and our results will help researchers find new therapies to treat diseases.”

The vagus nerve is made up of 100,000 individual fibers. It acts as an information pipeline in the body, stretching from the brain to the organs helping to maintain bodily functions and immune response. If the vagus nerve is overactive or underactive inflammatory diseases can arise. The field of bioelectronic medicine combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies using computer chips and devices instead of drugs to treat those diseases. By stimulating the vagus nerve with high frequency, Dr. Zanos and his team were able to consistently activate the small unmyelinated nerve fibers while at the same time bypassing the activation of larger fibers in the nerve – which are usually the first to be activated by VNS and are responsible for most unwanted side-effects. The study was done in two animal models (mice and rats) and if validated in humans, could be leveraged in novel bioelectronic therapies. “Dr. Zanos discovered how to selectively activate nerve fibers traveling in the vagus nerve by manipulating the electric frequency,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “This work significantly advances the field of bioelectronic medicine and opens new pathways to explore experimental therapeutics.” The Feinstein Institutes for Medical Research was recently awarded $6.7 million from the National Institutes of Health (NIH). The funding will help Dr. Zanos and his lab create a detailed map of the anatomy of the human vagus nerve. The funding is part of the NIH Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. Read the full article

[marketresearch-articles]

The Complete Guide to Depression screening market

Are you willing to know about Depression screening market? Then you are in right place. Here you will get information like Market Analysis and Insights: Depression screening market Service Market, Market Scope and Market Size, Depression screening market Country Level Analysis, Market Share Analysis, Customization Available

Depression Screening Market growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand.

major players covered in the depression screening market report are Johnson & Johnson Services Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co.Ltd., Pfizer Inc., GlaxoSmithKline plc, Allergan, Janssen Pharmaceuticals, Inc., Meiji Holdings Company, Ltd., Abbott, Jazz Pharmaceuticals, Inc., AbbVie Inc., 3M, Acadia Pharmaceuticals Inc., Medtronic, Bausch Health Companies Inc., and Merck KGaA, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Depression screening market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 14,328.12 billion by 2028 and will grow at a CAGR of 5.11% in the above mentioned forecast period.

Download Exclusive Sample Copy of the Anti-ageing products market Report to understand the structure of the complete Study Including Full TOC, Table & Figures @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-depression-screening-market

Market Segmentation

On the basis of disease type, the depression screening market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, eating disorders and others.

Based on diagnosis, the depression screening market is segmented into psychological test, lab tests, depression screening tests and others.

On the basis of treatment, the depression screening market is segmented into medication, brain-stimulation treatments and deep brain stimulation. Medication has further been segmented into anti-anxiety medications, antidepressants, antipsychotic medications, stimulants anti-seizures medications and others. Brain-stimulation treatments have further been segmented into vagus nerve stimulation (VNS), repetitive transcranial magnetic stimulation (rTMS) and magnetic seizure therapy (MST).

The end user segment of depression screening market is segmented into hospitals and clinics, medical research centers, academic institutes and others.Report Highlights

Detailed overview of the market

Changing dynamics of the market

 Market segmentation

The regional landscape of the market

Evaluation of the market based on the present and past data collected

Historical, present, and projected market in terms of volume and value

Recent trends and developments in the market

Competitive landscape

Strategies adopted by key players and products offered by them

Access Full Report@ https://www.databridgemarketresearch.com/reports/global-depression-screening-market

Customization Available : Global Depression Screening Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Browse related report @

Motorcycle Apparel Market

Pet Odor Control and Clean-up Products Market

Portable Air Coolers Market

Shampoo Market

[rdagade]

Global Nerve Repair and Regeneration Market

The

Global market for Nerve Repair and Regeneration

was valued at $xx Mn in 2020 and is expected to reach $xx Mn by 2027, at a CAGR of xx%. The prevalence of neurological disorders and chronic pain is increasing rapidly across the globe.

Depression, epilepsy, Parkinson’s, and Alzheimer’s are different kinds of neurological disorders. As per the Alzheimer’s Association, about 5.35 million people aged 65 years and above were suffering from Alzheimer’s diseases in the U.S. in 2015. Apart from this, as per the Parkinson’s Diseases Foundation, nearly 60,000 new cases of Parkinson’s disease are reported each year in the U.S. Due to these reasons, the demand for efficient medical technologies, such as Neuromodulation and Neurostimulation devices are increasing rapidly.

Furthermore, the nerve repair and regeneration market are witnessing significant growth due to the increasing geriatric population. The generation of the new axon, glial cells, neurons, and myelin is referred to as nerve repair and regeneration. The process helps in the replacement of damaged nerve cells, cellular products, and tissues. Neurostimulation & Neuromodulation devices and biomaterials are the products that are utilized for reversing the damage caused to the nerve.

Between these two, the largest demand is expected to be created for Neurostimulation and Neuromodulation devices in the coming years, due to increasing incidences of peripheral nerve injuries, favorable reimbursement policies, and technological advancements. Availability of a number of therapies for treating various Central Nervous System (CNS) disorders, such as Parkinson’s disease and Alzheimer’s, and increasing scope of applications is further expected to boost the market growth over the forecast period.

Increasing awareness, environmental influence, lifestyle, genetics, nutrition are some of the factors that can cause such disorders. The report contains detailed analysis of Strengths, Weakness and opportunities of the key players operating in the Nerve Repair and Regeneration Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.

Global Nerve Repair and Regeneration Market Segment Analysis

Neurostimulation and Neuromodulation Devices held the largest share of xx% in 2020 Based on the product, the market is segmented as Neurostimulation and Neuromodulation Devices. The segment is further sub-segmented into internal Neurostimulation and external Neurostimulation devices and biomaterials. Neurostimulation and Neuromodulation Devices was the largest segment which held a significant share of xx% in 2020 and is expected to grow at a CAGR of xx%. The largely available spinal cord products and a wider range of applications for the same were responsible for the market growth.

The internal Neurostimulation devices segment is again segmented into- Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES). The segment growth for internal Neurostimulation devices is expected to boost in the forecast period. Investments of top players of the market in the new launching of more advanced devices is a major driver for the Neurostimulation and Neuromodulation Devices market. On 23 July 2020, the US Food and Drug Administration (FDA) approved Abbott's Patient Controller App’ on compatible personal Apple smartphone devices. According to Abbott, this approval allows patients living with neurological conditions, including chronic pain or movement disorders, the ability to manage therapy directly from their personal smartphone. Such advancements are boosting the market growth.

Based on applications, the Stem cell therapy segment is expected to witness the fastest CAGR due to the various government initiatives and approvals to conduct clinical trials of biomaterials. A high number of research centers, universities, and companies, from European nations, the United States, and Canada, are also conducting several clinical trials for the application of stem cell-based therapies in nerve repair and regeneration. These countries are found to be backed by high government funding, well-developed healthcare infrastructure, and widespread global presence. Due to the above factors, the segment is expected to show a growth market over the forecast period.

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-nerve-repair-and-regeneration-market/83571/

Scope of the Global Nerve Repair and Regeneration Market : Inquire before buying

Global Nerve Repair and Regeneration Market Segmentation

The Global Nerve Repair and Regeneration Market is segmented based on-

Global Nerve Repair and Regeneration Market Product

• Neurostimulation and Neuromodulation Devices  Internal Neurostimulation Devices  Spinal Cord Stimulation (SCS)  Deep Brain Stimulation (DBS)  Vagus Nerve Stimulation (VNS)  Sacral Nerve Stimulation (SNS)  Gastric Electrical Stimulation (GES)  External Neurostimulation Devices  TENS  TMS  RES  Biomaterials  Nerve Conduits  Nerve Wraps

Global Nerve Repair and Regeneration Market Applications

• Neurostimulation and Neuromodulation Applications  Internal Neurostimulation and Neuromodulation Applications  External Neurostimulation and Neuromodulation Applications • Direct Nerve Repair/Neurorrhaphy  Epineural Repair  Perineural Repair  Group Fascicular Repair • Nerve Grafting  Auto grafts  Allografts  Xeno grafts • Stem Cell Therapy

To know about the Research Methodology :-

Request Free Sample Report

Global Nerve Repair and Regeneration Market Regional Insights

North America accounted for the largest share of Global Nerve Repair and Regeneration Market in 2020 North America accounted for the largest share of xx% in 2020, the reason being the rising prevalence of neural disorders. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Investments by key players in this field have boosted the market growth. For instance, on December 24, 2020, Soterix Medical announced expanded clinical trials of its transcranial direct current stimulation system in Alzheimer’s disease. Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand.

Key Players operating in the Global Nerve Repair and Regeneration Market

• Medtronic, PLC • Boston Scientific Corporation • Abbott Laboratories • AxoGen, Inc • Baxter International • LivaNova, PLC • Integra Lifesciences • Polyganics • NeuroPace • Soterix Medical, Inc • Nvero Corp • Synapse Biomedical, Inc • Aleva Neurotherapeutics • Collagen Matrix • KeriMedical • BioWave Corporation • NeuroSigma • tVNS Technologies GmbH • GiMer Medical The report also helps in understanding Global Nerve Repair and Regeneration Market dynamics, structure by analysing the market segments and project Global Nerve Repair and Regeneration Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Nerve Repair and Regeneration Market make the report investor’s guide.

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

[sapanas]

Vagal Nerve Stimulation (VNS) Market Analysis 2018-2023 by Latest Trends, Development, Future Growth, Revenue Forecast With Impact Analysis of COVID-19, Demand Forecast

Vagal nerve stimulation (VNS) is a method used for delivering electrical impulses to the vagus nerve. The vagus nerve acts as a translator between the gut and the brain. The method involves the implantation of a device under the clavicle with lead wires being wrapped around the vagus nerve for sending out electrical impulses. The global vagal nerve stimulation market report by Market Research Future (MRFR) compiled by reputed analysts enumerates drivers, challenges, and opportunities in a comprehensive manner.

Vagal Nerve Stimulation (VNS) Market Overview

The global vagal nerve stimulation market size is expected to balloon at 8.68% CAGR during the forecast period (2017-2023). Rise in number of neurological disorders such as epilepsy, depression, migraine, and others is one of the biggest drivers of the market. According to the World Health Organization (WHO), neurological disorders accounted for 4.5-11% of all diseases in low-income and mid-income economies. High need for better treatment techniques and influx of capital into research and development by pharmaceutical and biotechnology firms can create opportunity of growth for the market.

Development of novel technologies for epilepsy treatment and favorable reimbursement policies proposed by governments in alliance with health coverage companies can persuade patients for the treatment. Research for the management and treatment of muscle function and organ disorders is likely to widen the scope of VNS manufacturers in the market.

Paucity of skilled surgeons and high costs of neurostimulation devices can pose a challenge to the market growth. Side-effects of cardiac arrest and probability of triggering a stroke can lead to hesitancy among doctors for prescribing the treatment.

Vagal Nerve Stimulation (VNS) Market Segmentation

The global vagal nerve stimulation market is segmented by product, application, and end-user.

By product, it is segmented into external VNS devices and implantable VNS devices.

By application, it is segmented into migraine, epilepsy, depression, and others.

By end-user, it is segmented into ambulatory surgical centers, hospitals, and others.

Vagal Nerve Stimulation (VNS) Market Regional Analysis

Asia Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA) are major regions discussed in the global vagal nerve stimulation market.

The Americas accounted for 43% market share in 2016. Rising government support for research and development into neurological disorders, high healthcare spending, and sophisticated healthcare infrastructure and framework for major manufacturers to enter the region can bode well for the market growth. Presence of large players as well as their increased capacity to invest in sufficient amount of capital can encourage the market proliferation during the forecast period.

Europe holds the second position in the market standings due to availability of sufficient funds for research and development and rise in government support. On the other hand, the APAC region has latent potential for growth due to economies of China, South Korea, Japan, and India. The increased healthcare budget of economies, large patient pool, and development of neurostimulation technology are factors which can boost the regional market growth.

Lastly, the MEA region can offer limited returns growth and revenue-wise due to insufficient funding by governments and a paucity of healthcare infrastructure.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/vagal-nerve-stimulation-market-4479

Vagal Nerve Stimulation (VNS) Market Competition Outlook

LivaNova PLC, ElectroCore Medical LLC, EnteroMedics Inc., NeuroMetrix, Inc., Boston Scientific Corporation, Inspire Medical Systems, Inc., Cyberonics, Inc., ImThera Medical, and others are prominent names currently operational in the global vagal nerve stimulation market. Collaborations between medical device manufacturers and hospitals for measuring the efficacy of devices is likely to result in faster development of effective devices. For instance, the Massachusetts General Hospital decided to collaborate with electroCore, Inc., for attaining sufficient clinical trial data for gauging the performance of VNS Therapy for treatment of depression, migraine, and other neurological disorders.

Recently, LivaNova PLC was celebrating the success of its proprietary VNS Therapy System by proving to be effective for the treatment of drug-resistant epilepsy (DRE).